Get the Stockscreener App
12.47
7.59%
0.88
Oric Pharmaceuticals Inc stock is traded at $12.47, with a volume of 487.99K.
It is up +7.59% in the last 24 hours and up +0.89% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$11.59
Open:
$11.74
24h Volume:
487.99K
Relative Volume:
0.33
Market Cap:
$1.29B
Revenue:
Net Income/Loss:
$-135.21M
P/E Ratio:
-8.7136
EPS:
-1.4311
Net Cash Flow:
$-114.35M
1W Performance:
+3.66%
1M Performance:
+0.89%
6M Performance:
+21.30%
1Y Performance:
-10.29%
1-Day Range:
$11.53
$12.56
1-Week Range:
$11.20
$12.29
52-Week Range:
$7.23
$14.68
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.47 | 1.29B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
510.35 | 129.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.71 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.17 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.00 | 41.97B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Initiated | Leerink Partners | Outperform |
| Sep-23-26 | Initiated | BTIG Research | Buy |
| Jun-12-26 | Resumed | Stifel | Buy |
| May-15-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Nov-20-25 | Initiated | Evercore ISI | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Oric Pharmaceuticals director Heyman sells $86,524 in ORIC stock By Investing.com - Investing.com South Africa
Form 4 Oric Pharmaceuticals Inc: Richard A. Heyman (Director) For: 1 October - Investing.com UK
Cancer Research UK will fund early testing of a potential cancer treatment. - stocktitan.net
A director exercised options at $1.60 and sold 3,500 Oric Pharmaceuticals (ORIC) shares. - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new hires received options to buy shares and stock awards from ORIC Pharmaceuticals - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
A director proposes selling 8,100 shares of Oric Pharmaceuticals (ORIC). - Stock Titan
A proposed sale covers 7,600 Oric Pharmaceuticals (ORIC) shares held by RAHD Capital. - Stock Titan
Oric Pharma CFO sells $181k in shares By Investing.com - Investing.com South Africa
Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
Oric Pharma CFO sells $181k in shares - Investing.com
Form 4 Oric Pharmaceuticals Inc For: 29 September - Investing.com India
Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com UK
After a $4.36 option exercise, Oric Pharmaceuticals (ORIC) CFO sells 13,400 shares. - stocktitan.net
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18 - MarketBeat
1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE - MarketBeat
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares - Investing.com
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares By Investing.com - Investing.com Canada
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com India
A finance chief exercised 600 options and sold 600 shares at Oric Pharmaceuticals (ORIC). - stocktitan.net
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com UK
ORIC Pharmaceuticals (Nasdaq:ORIC)Stock Analysis - Simply Wall Street
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.com.au
Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC - marketbeat.com
Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones - Stock Traders Daily
ORIC: Advancing late-stage prostate and lung cancer programs with robust funding and global trials - TradingView
ORIC: Phase III trials and robust funding position support late-stage oncology pipeline growth - TradingView
ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com Canada
ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com India
Oric Pharmaceuticals joins 2026 Cantor Global Healthcare Conference fireside chat: Can ORIC break above $12.51? - Traders Union
ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView
ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
ORIC stock holds firm as biotech valuation nears 0.93 billion USD - ad-hoc-news.de
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.ca
Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - ad-hoc-news.de
Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan
Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing - Yahoo Finance
ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month HighHere's Why - MarketBeat
Oric (ORIC) Earnings Report: EPS Misses Its Estimate in Latest Trading; After Earnings: The Stock Gains 4.04% in the Latest SessionForward EPS Estimate - vinanet.vn
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Richard A, Heyman | Director |
Oct 01 '26 |
Proposed Sale |
13.47 |
8,100 |
109,107 |
0 |
| Richard A, Heyman | Director |
Oct 01 '26 |
Proposed Sale |
13.47 |
7,600 |
102,372 |
0 |
| Heyman Richard A. | Director |
Oct 01 '26 |
Sale |
12.91 |
3,500 |
45,199 |
38,300 |
| Heyman Richard A. | Director |
Oct 01 '26 |
Sale |
12.91 |
3,200 |
41,325 |
203,472 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 28 '26 |
Sale |
13.53 |
13,400 |
181,258 |
69,828 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 28 '26 |
Option Exercise |
4.36 |
13,400 |
58,424 |
83,228 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 24 '26 |
Sale |
13.50 |
600 |
8,102 |
69,828 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 24 '26 |
Option Exercise |
4.36 |
600 |
2,616 |
70,428 |
| Dominic Piscitelli | Officer |
Aug 26 '26 |
Proposed Sale |
13.50 |
229,500 |
3,098,250 |
0 |
| Piscitelli Dominic | Chief Financial Officer |
Aug 26 '26 |
Sale |
13.69 |
77,000 |
1,053,814 |
69,828 |
2.25%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):